Skip to main content
Equibles
SLDB logo

SLDB · Solid Biosciences Inc.

Track SLDB — free

Use SLDB with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$10.25 -0.04 (-0.39%)
Russell 2000 member Rebalance outlook locked
Market Cap
$1.08B
Shares
107.23M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$10.29 Open$9.92 Day$9.75–10.44 52W close$3.93–11.15 Avg vol 30d907K Short int16.6M · 15.5% float · 19.6d Short vol72% Last earningsFeb 18, 2025 DataOct 2022–Sep 2026 Filing10-Q · Aug 6

Raw chart and full-history price indicators begin at the captured split on Oct 28, 2022; bars on opposite sides are not compared.

Up next

Latest filing: 10-Q
filed Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$207.10M
Trailing 12 months
Revenue growth YoY
-40.6%
Year over year
Operating margin
-1,315.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-17.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$159.39M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+52.6%
Year over year · more shares
Price change (1Y)
+89.4%
Trailing year
Short interest
15.5%
Latest settlement · 19.6 days to cover
View all 114 metrics

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Strong Buy Momentum Very Strong Sentiment Bullish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 15.2 · calm Equity put/call 0.56
Technical
price trend
Strong Buy
50 / 200-day cross No cross
Price vs 200-day avg +42%
above
Price vs 50-day avg +11%
above
RSI (14) 63
neutral
MACD trend Positive
52-week position 88%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +18%
trailing
6-month return +33%
trailing
YTD return +82%
this year
Relative strength +19%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $9 › 200d $7 — 50d above 200d
Institutional flow Accumulating
+3% holders QoQ · +36 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
15.50% of float · ▼ -2.4% MoM · 19.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
156 holders — near 3-yr high, broad support
Squeeze score 87
high risk · 0–100
Fundamentals
Weak
Revenue growth −41%
Y/Y
EPS growth +35%
Y/Y
Free cash flow $-157.4M
Quant / Vol
risk profile
Very High
Volatility 80%
annualized · 1-yr
Max drawdown −39%
past year
ATR 5.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Buy
0 · 3 · 4
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+42% Bullish
Price vs 50-day avg
+11% Bullish
RSI (14)
63 Neutral
MACD trend
Positive Bullish
52-week position
88% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $9 › 200d $7 — 50d above 200d
Institutional flow Accumulating
+3% holders QoQ · +36 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
15.50% of float · ▼ -2.4% MoM · 19.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
156 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $4 Now $10 · 88% Range high $11
vs 200-day avg +42% vs 50-day avg +11%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SLDB
Solid Biosciences Inc.
this stock
$1.08B +82.4% -40.6% — 15.5%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $140.51B +22.8% +46.2% 32.3 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $84.82B +10.4% +20.8% 20.4 2.3%
ARGX
Argenx SE
 $65.63B +25.5% — — 1.9%
MRNA
Moderna, Inc.
 $61.59B +411.4% +4.3% — 13.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
156
% held
107.0%
Net QoQ
+14.6M sh
Top holder
RA CAPITAL MANAGEMENT, L.…
Held Float
View
Held by Funds
Fund positions
146
View
Short & Settlement
Short Interest Falling
Shares short
16.6M
Days to cover
19.6d
Change
-416.4K sh
View
Short Volume
Short vol %
72%
As of
Sep 2, 2026
Short Total
View
Fails to Deliver
FTD shares
1.2K
Value
$10.9K
As of
Aug 14, 2026
View
Off-Exchange
Off-exchange %
29.3%
Week of
Jul 27, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$8.1M
Net income (FY)
$-117.2M
EPS diluted
$-1.99
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 6, 2026
This year
9
View
Proposed Sales
Value
$43.5K
Shares
7.5K
Filed
Feb 18, 2026
View
Exempt Offerings
Offering
$9.2M
Filed
Dec 9, 2022
View
Earnings & Events
Earnings Calls
Last call
Feb 18, 2025
View

Performance

Raw-price comparisons begin at the captured split on Oct 28, 2022; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
SLDB +5.8% +17.8% +33.4% +7.4% +82.4%
SPY -0.1% -0.6% +14.9% -0.3% +12.2%
vs SPY +5.9% +18.4% +18.5% +7.6% +70.2%
Key facts CIK 1707502 CUSIP 83422E204 13F (30d) 140 filings 137 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)